Stelara

This page shows the latest Stelara news and features for those working in and with pharma, biotech and healthcare.

New data keeps AbbVie’s star pipeline therapies on track

The analysis concentrated on patient-reported outcomes data from two studies that compared risankizumab to J&J’s $4bn-a-year IL-12/IL-23 inhibitor Stelara (ustekinumab) and one against ... The analysis showed that 56% of patients on risankizumab were

Latest news

BMS psoriasis drug hits the mark in phase II

including Johnson &Johnson’s Stelara (ustekinumab) and follow-up Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab) and AbbVie’s recently-filed risankizumab.
AstraZeneca’s Lupus treatment misses mark in trial

Its blockbuster Stelara produced encouraging phase II results in the disease last November, while Gilead is working with Verily on an early stage research project to better understand the disease.
UK, Germany back routine use of J&J’s Tremfya

Tremfya (guselkumab) is a follow-up to J&J’s IL-23/IL-12 inhibitor Stelara (ustekinumab) that rakes in blockbuster revenues but is facing the threat of competition from newer ... Stelara was a $4bn product for J&J’s Janssen Pharma unit last year, but
Sun Pharma passes milestone with novel psoriasis drug approval

Johnson &Johnson's IL-12/IL-23 blocker Stelara (ustekinumab) was the first interleukin drug to reach the market and swiftly reached blockbuster sales level, and has since been joined by
AbbVie reports more solid data for would-be psoriasis blockbuster

AbbVie reports more solid data for would-be psoriasis blockbuster. Risankizumab showed to be more effective in plaque psoriasis patients than J&J’s Stelara. ... A pair of phase III trials pitting risankizumab against Johnson &Johnson’s older

More from news
Approximately 14 fully matching, plus 59 partially matching documents found.

Latest Intelligence

Taking a strategic approach

Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of ... Stelara at the same cost as the 45 mg dose (one vial) for
Back to the future

Likewise, J&J had a strong year - with eight of its key products, including Zytiga, Xarelto, Remicade, Stelara and Invega Sustenna/Xeplion, driving collective growth of more than $3.5bn (10

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Healthcare PR Director: £100, 000 – £120, 000 benefits

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Senior Account Manager – Healthcare Advertising: Salary TBC

Graduate Scientific Editor: DOE

Medical Writer - Creative and Scientific Projects: DOE

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Account Manager: Negotiable

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Training Manager - Surrey: Competitive Salary &Bonus

Associate Scientific Director: Salary TBC

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Account Director, Healthcare Advertising Agency: Salary TBC

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Healthcare PR Senior Account Manager: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Account Director or Senior Account Director: Salary TBC

Senior Writer, Healthcare Advertising, London: Excellent package

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Account Manager- 4 days per week or full-time: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

The gene therapy revolution: Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...